Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05373953
Other study ID # CLI-06001AA1-08
Secondary ID 2021-003729-31
Status Completed
Phase Phase 1
First received
Last updated
Start date May 5, 2022
Est. completion date November 25, 2022

Study information

Verified date April 2024
Source Chiesi Farmaceutici S.p.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A clinical trial to investigate the pharmacokinetics, safety and tolerability of CHF6001 after single administrations in participants with mild, moderate and severe liver impairment with matched healthy adult volunteers


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date November 25, 2022
Est. primary completion date November 25, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: - All subjects: 1. Subject's written informed consent obtained prior to any study-related procedure; 2. Ability to understand the study procedures and the risks involved, and ability to be rained to use the inhalers correctly and to generate sufficient peak inspiratory flow (PIF; at least 40 L/min) using the In- Check DIAL set as per NEXThaler® inhaler resistance; 3. 12-Lead digitised electrocardiogram (ECG) in triplicate considered as normal (40 beats per minute [bpm] = heart rate [HR] = 110 bpm, 120 ms = PR interval [PR] = 210 ms, QRS interval [QRS] = 120 ms, QT Interval corrected using Fridericia's formula [QTcF] = 450 ms for males and QTcF = 470 ms for females) at screening visit. The mean value must be within the defined range; 4. Male and female subjects aged 40 to 80 years inclusive; 5. Subjects must weigh at least 45 kg for females and 50 kg for males to participate in the study, and must have a body mass index within the range of 18 to 35 kg/m2 inclusive; 6. Non- or ex-smokers who smoked < 5 pack-years (pack-years = the number of cigarette packs per day times the number of years) and stopped smoking > 1 year prior to screening; 7. Female subjects: a. Women of childbearing potential (WOCBP) fulfilling one of the following criteria: i. WOCBP with fertile male partners: they and/or their partner must be willing to use at least an acceptable effective birth control method from the signature of the informed consent and until study discontinuation; or ii. WOCBP with non-fertile male partners (contraception is not required in this case); b. Female subjects of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. post-menopausal or permanently sterile. Tubal ligation or partial surgical interventions are not acceptable. 8. Vital signs within normal limits at screening: diastolic blood pressure (DBP) 40-89 mmHg and systolic blood pressure (SBP) 90-139 mmHg, extremes included (two measures performed after at least 5 minutes of resting). 9. Body temperature < 37.5°C at screening and prior to study treatment administration; 10. Lung function measurements within normal limits at screening: forced expiratory volume within the first second (FEV1) > 80% predicted and FEV1/forced vital capacity (FVC) ratio > 0.70; Healthy subjects only: 11. Good mental and physical status, determined on the basis of the medical history and a general clinical examination, at screening and prior to study treatment administration; 12. Matched to at least one liver impaired subject enrolled in the study with respect to race, gender, age (±10 years) and body weight (±15%) Liver impaired subjects only: 13. Documented chronic stable liver disease based on the Child-Pugh score and classification (Child-Pugh Class A [mild], B [moderate] or C [severe]) at screening and on Day -1: 14. Liver impairment must be caused by hepatic primary disease, not a complication of other underlying diseases. Exclusion Criteria: - All subjects: 1. For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test. Serum pregnancy test to be performed at screening and urine pregnancy test to be performed prior to study treatment administration; 2. Subjects with history of breathing problems (i.e. history of asthma including childhood asthma); 3. Positive human immunodeficiency virus (HIV) 1 or HIV2 serology at screening; 4. Subject has pre-planned surgery or procedures that would interfere with the conduct of the study; 5. Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks, or complications from this disease, which has not resolved within 14 days prior to screening or prior to study treatment administration; 6. Blood donation or blood loss (= 450 mL) less than 2 months prior to screening or prior to study treatment administration; 7. Abnormal haemoglobin level defined as < 13 g/dL for males and < 11 g/dL for females at screening; 8. Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen evaluated at screening or prior to study treatment administration; 9. Intake of non-permitted concomitant medications in the predefined period prior to screening or prior to study treatment administration, or the subject is expected to take non-permitted concomitant medications during the study 10. Unsuitable veins for repeated venepuncture; 11. Participation in another clinical study where an investigational treatment was received, and last investigations were performed less than 8 weeks prior to screening; 12. Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or to study treatment administration; 13. Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the study; 14. Heavy caffeine drinker (average of > 5 cups or glasses per day of caffeinated beverages e.g. coffee, tea, cola, calculated by number of standard espresso portions); 15. Positive urine test for cotinine at screening or prior to study treatment administration; 16. Contra-indications/warnings/precaution for use: contra-indications to the investigational medicinal product constitute an exclusion criterion. For warnings/precaution for use, eligibility will be judged by the Investigator; 17. The use of any kind of smoking electronic devices within 6 months before screening and before study treatment administration; 18. Clinically relevant and/or uncontrolled cardiovascular, renal, gastrointestinal, haematological, endocrine, metabolic, respiratory, neurologic, neoplastic or psychiatric disorder that, based on the Investigator's judgment, may interfere with successful completion of this study. Healthy subjects only: 19. Any hepatic disorder that, based on the Investigator's medical judgment, may interfere with successful completion of this study; 20. Positive results from the hepatitis serology which indicate acute or chronic hepatitis B or hepatitis C (e.g. positive hepatitis B surface antigen [HBsAg], hepatitis B core antibody [immunoglobulin M antibody to hepatitis B core antigen; IgM anti-HBc], hepatitis C virus [HCV] antibody); Note: Subjects with an isolated antibody to HBsAg (anti-HBs) positive result, immune due to a medical history of vaccination, are permitted; 21. Abnormal liver enzymes at screening or prior to study treatment administration (alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transpeptidase, alkaline phosphatase or total bilirubin; ALT or AST > 1.5 times the upper limit of normal [ULN], bilirubin > 1.5 times the ULN); 22. Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test at screening or prior to study treatment administration; 23. Clinically relevant abnormal laboratory values at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the result of the study according to the Investigator's judgment; Liver impaired subjects only: 24. Impaired renal function (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2) due to primary or secondary renal disease (e.g. hepatorenal syndrome); 25. Documented history of alcohol abuse within at least 3 months prior to screening or a positive alcohol breath test at screening or prior to study treatment administration; 26. Severe complications of liver disease within the preceding 3 months prior to enrolment (e.g. Grade 3-4 encephalopathy, severe ascites, severe haemostatic impairment, gastrointestinal haemorrhage, spontaneous bacterial peritonitis or emergency room visit/hospitalisation due to liver disease);

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CHF6001
CHF6001 will be administered using the NEXThaler® DPI device

Locations

Country Name City State
Bulgaria MC Comac Medical Ltd. Sofia

Sponsors (1)

Lead Sponsor Collaborator
Chiesi Farmaceutici S.p.A.

Country where clinical trial is conducted

Bulgaria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetic parameter (Cmax) Peak Plasma Concentration (Cmax) for CHF6001 for total plasma Over 240 hours after administration in blood
Primary Pharmacokinetic parameter (AUCt) Area under the plasma concentration versus time curve (AUCt) for CHF6001 for total plasma Over 240 hours after administration in blood
Secondary Pharmacokinetic parameter ( Cmax) Peak Plasma Concentration (Cmax) for CHF6001 unbound plasma Over 240 hours after administration in blood
Secondary Pharmacokinetic parameter (AUCt) Area under the plasma concentration versus time curve (AUCt) for CHF6001 unbound plasma Over 240 hours after administration in blood
Secondary Pharmacokinetic parameter (AUC0-72) Area under plasma concentration from 0 to 72hours (AUC0-72) for CHF6001, CHF5956 and CHF6095 Over 72 hours after administration in blood
Secondary Pharmacokinetic parameter (AUC0-240) Area under plasma concentration from 0 to 240hours (AUC0-240) for CHF6001, CHF5956 and CHF6095 Over 240 hours after administration in blood
Secondary Pharmacokinetic parameter (AUC0-8) Area under plasma concentration from 0 to infinity(AUC0-8) for CHF6001, CHF5956 and CHF6095 Over 240 hours after administration in blood
Secondary Pharmacokinetic parameter (tmax) Time of the maximum plasma concentration (tmax) for CHF6001, CHF5956 and CHF6095 Over 240 hours after administration in blood
Secondary Pharmacokinetic parameter (t1/2) Terminal half-life (t1/2) for CHF6001, CHF5956 and CHF6095 Over 240 hours after administration in blood
Secondary Pharmacokinetic parameter (CL/F) Apparent systemic clearance (CL/F) for CHF6001 Over 240 hours after administration in blood
Secondary Pharmacokinetic parameter (AUCt) Area under the plasma concentration versus time curve (AUCt) for CHF5956 and CHF6095 Over 240 hours after administration in blood
Secondary Pharmacokinetic parameter (Cmax) Peak Plasma Concentration (Cmax) for CHF5956 and CHF6095 Over 240 hours after administration in blood
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy